Sodium Oxybate Solution
NDC Package 72865-349-18

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Sodium Oxybate solution is a medication used to treat narcolepsy, a condition that causes severe daytime sleepiness. This formulation utilizes a solution delivery system. Marketed by Xlcare Pharmaceuticals, Inc., this product is identified by NDC 72865-349 and is authorized under FDA application ANDA210523.

Identification & Billing

NDC Package Code
72865-349-18
Package Description
1 BOTTLE in 1 CARTON / 180 mL in 1 BOTTLE
Product Code
72865-349
11-Digit Billing Format
72865034918
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Sodium Oxybate
Non-Proprietary Name
Sodium Oxybate
Substance Name
Sodium Oxybate
Dosage Form
Solution - A clear, homogeneous liquid1 dosage form that contains one or more chemical substances dissolved in a solvent or mixture of mutually miscible solvents.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
SODIUM OXYBATE .5 g/mL
Pharmacologic Class
Usage Information
This medication is used to treat narcolepsy, a condition that causes severe daytime sleepiness. Sodium oxybate can decrease daytime sleepiness and also reduce the number of sudden short attacks of weak/paralyzed muscles (known as cataplexy) that can occur in patients with narcolepsy. Sodium oxybate is a central nervous system depressant. It is also known as gamma hydroxybutyrate (GHB).
DEA Schedule
Schedule III (CIII) Substances

Regulatory & Marketing

Labeler Name
Xlcare Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA210523
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
01-01-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 72865-349-18 identifies a specific commercial package of 1 bottle in 1 carton / 180 ml in 1 bottle of Sodium Oxybate, a human prescription drug labeled by Xlcare Pharmaceuticals, Inc.. This solution is formulated for oral use and contains sodium oxybate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Xlcare Pharmaceuticals, Inc. on January 01, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

This medication is used to treat narcolepsy, a condition that causes severe daytime sleepiness. Sodium oxybate can decrease daytime sleepiness and also reduce the number of sudden short attacks of weak/paralyzed muscles (known as cataplexy) that can occur in patients with narcolepsy. Sodium oxybate is a central nervous system depressant. It is also known as gamma hydroxybutyrate (GHB).

How is this Xlcare Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 72865034918. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
72865-349-18
11-Digit CMS (5-4-2)
72865-0349-18

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.